BeiGene, Ltd. (ONC)vsPluri Inc. (PLUR)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
PLUR
Pluri Inc.
$3.05
-0.33%
HEALTHCARE · Cap: $34.09M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 399828% more annual revenue ($5.34B vs $1.34M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
PLUR
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for PLUR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
3.1% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : PLUR
PLUR has a balanced fundamental profile.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : PLUR
The primary concerns for PLUR are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while PLUR is a value play — different risk/reward profiles.
PLUR carries more volatility with a beta of 0.57 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 24/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Pluri Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Pluri Inc. is a cutting-edge biotechnology company specializing in regenerative medicine and immunotherapy, with a strong emphasis on developing innovative cell-based therapies. Utilizing its proprietary technology platform, Pluri aims to tackle significant unmet medical needs in oncology and degenerative diseases. The company boasts a robust pipeline and strategic partnerships that position it to improve patient outcomes and capitalize on growth opportunities within the dynamic healthcare landscape. By focusing on the transformative potential of human cells, Pluri is establishing itself as a key player in the biotechnology industry, committed to advancing novel therapeutic solutions.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?